Related Experiment Video
Updated: Aug 17, 2026
Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line
Published on: April 11, 2025
Analysis of genomic DNA alterations and mRNA expression patterns in a panel of human pancreatic cancer cell lines
Stephan Gysin1, Paula Rickert, Kumar Kastury
1Cancer Research Institute and Department of Cellular and Molecular Pharmacology, University of California, San Francisco Comprehensive Cancer Center, San Francisco, California, USA.
Abstract:
Genomic alterations influencing the expression and/or activity of tumor suppressors or oncogenes such as KRAS2, CDKN2A, TP53, and DPC4 have been directly implicated in the initiation and progression of human pancreatic adenocarcinoma. In an effort further to systematically characterize the genomic alterations that occur in this disease, we conducted a genome wide analysis of alterations in gene copy number using array-based comparative genomic hybridization (CGH). For this analysis, we utilized a panel of 25 human pancreatic cancer cell lines derived from either primary or metastatic tumors. This panel also included a metastatic progression series of cell lines derived from COLO 357 cells. Array CGH permitted the identification of alterations in the copy number of genes that might participate in the aberrant behavior of pancreatic cancer cells. In addition, the acquisition of invasive and metastatic potential by derivatives of COLO 357 cells was accompanied by additional focal genomic alterations including point mutations and amplification of KRAS2. To complement the array CGH analysis, we also conducted an analysis of mRNA expression patterns in a subset of these cells using cDNA microarrays. By this means, we identified a set of candidate genes, including those regulated by RAS signaling, that may contribute to the process of cancer cell invasion and metastasis. Supplementary material for this article can be found on the Genes, Chromosomes, and Cancer website at http://www.interscience.wiley.com/jpages/1045-2257/suppmat/index.html.
Insights
Genomic analysis of pancreatic cancer cell lines revealed copy number alterations in key genes. These changes, particularly in KRAS2, correlate with increased invasion and metastasis, offering insights into pancreatic adenocarcinoma progression.
Area of Science:
- Genomics
- Cancer Biology
- Molecular Oncology
Background:
- Genomic alterations in tumor suppressors and oncogenes (e.g., KRAS2, CDKN2A, TP53, DPC4) are crucial in pancreatic adenocarcinoma development.
- Systematic characterization of these genomic changes is essential for understanding disease initiation and progression.
Purpose of the Study:
- To systematically identify genomic alterations in human pancreatic cancer using a comprehensive genome-wide approach.
- To investigate the relationship between genomic changes and the acquisition of invasive and metastatic potential in pancreatic cancer cells.
Main Methods:
- Genome-wide analysis of gene copy number alterations using array-based comparative genomic hybridization (CGH) on 25 human pancreatic cancer cell lines.
- Analysis of mRNA expression patterns using cDNA microarrays to identify candidate genes involved in invasion and metastasis.
- Utilized a metastatic progression series derived from COLO 357 cells to study stepwise acquisition of malignant potential.
Main Results:
- Array CGH identified numerous gene copy number alterations in pancreatic cancer cell lines.
- Focal genomic alterations, including KRAS2 amplification and point mutations, were observed during the metastatic progression of COLO 357 derivatives.
- mRNA expression analysis highlighted candidate genes, including those in RAS signaling pathways, potentially driving cancer cell invasion and metastasis.
Conclusions:
- Genomic alterations, particularly copy number changes and specific mutations like KRAS2 amplification, play a significant role in pancreatic adenocarcinoma.
- The study identified potential molecular drivers of invasion and metastasis, providing targets for further investigation in pancreatic cancer therapy.
- This research offers a comprehensive genomic landscape of pancreatic cancer cell lines, contributing to a deeper understanding of the disease's molecular basis.
